Hood River Capital Management’s Coherus Oncology CHRS Stock Holding History

Hood River Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-386,932	Closed	-$7.1M	–	112
2020 Q3	$7.1M	Sell	386,932 -280,096	-42%	-$5.21M	0.31%	87
2020 Q2	$11.9M	Sell	667,028 -69,527	-9%	-$1.18M	0.53%	73
2020 Q1	$11.9M	Sell	736,555 -284,606	-28%	-$5.26M	0.68%	51
2019 Q4	$18.4M	Sell	1,021,161 -16,248	-2%	-$300K	0.79%	58
2019 Q3	$21M	Buy	1,037,409 +270,598	+35%	+$5.41M	1.07%	38
2019 Q2	$16.9M	Buy	+766,811	New	+$13.3M	0.8%	57

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Hood River Capital Management's CHRS Position: Q4 2020 in Review

Hood River Capital Management sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 386,932 shares — an estimated $7.1M sold.

Hood River Capital Management first reported a position in CHRS in Q2 2019 and held it in 6 quarters. The position peaked at $21M in Q3 2019. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

Hood River Capital Management reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
Hood River Capital Management sold 386,932 Coherus Oncology shares in Q4 2020, an estimated $7.1M.
Hood River Capital Management first reported a position in Coherus Oncology in Q2 2019 and held it in 6 quarters.
Hood River Capital Management's Coherus Oncology position peaked at $21M in Q3 2019.
196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on Hood River Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.